Non Small Cell Lung Cancer (NSCLC) remains the leading cause of death by cancer in the world. Because of the increase in lung cancer incidence with age and the increase of life expectancy, about half of the patients are patients aged 70 or older. Several clinical trials have shown the interest of adding immunotherapy to standard 1st line chemotherapy in NSCLC. Although in these studies there was not necessarily a higher age limit, in fact the proportion of included patients aged 75 or older remains low (between 7 and 10%). It is therefore necessary to conduct a trial dedicated to these patients in order to determine whether immunotherapy is as effective and tolerated as in the general population.
Name: Carboplatin
Description: AUC 6 every 4 weeksType: DrugArm A : standard treatment Arm B : standard treatment + immunotherapy
Name: Paclitaxel
Description: 90 mg/m² D1, 8, 15, every 4 weeksType: DrugArm A : standard treatment Arm B : standard treatment + immunotherapy
Name: Atezolizumab
Description: 1200 mg every 3 weeksType: DrugArm B : standard treatment + immunotherapy
Description: Time from randomization until death due to any cause
Measure: Overall Survival Time: 11 months after randomization of the last subjectDescription: Time from randomization to first observation of progression (according to RECIST v1.1) or date of death (from any cause).
Measure: Progression-free survival Time: 11 months after randomization of the last subjectDescription: Best response according to RECIST v1.1 from start to end of study treatment
Measure: Best overall response rate Time: 11 months after randomization of the last subjectDescription: Time from documentation of tumor response to disease progression
Measure: Duration of response Time: 11 months after randomization of the last subjectAllocation: Randomized
Parallel Assignment
There are 2 SNPs
Exclusion Criteria: 1. Small cell lung cancer or tumors with mixt histology including a SCLC component 2. Known EGFR activating tumor mutation (deletion LREA in exon 19, L858R ou L861X mutations in exon 21, G719A/S mutation in exon 18) or HER2 exon 20 insertion (either tissue or plasma cfDNA mutation). --- L858R --- --- G719A ---
Exclusion Criteria: 1. Small cell lung cancer or tumors with mixt histology including a SCLC component 2. Known EGFR activating tumor mutation (deletion LREA in exon 19, L858R ou L861X mutations in exon 21, G719A/S mutation in exon 18) or HER2 exon 20 insertion (either tissue or plasma cfDNA mutation). --- L858R ---